In conclusion, we demonstrated for the first time that estrogen- and antiestrogen-induced migration of endometrial cancer cells was through GPR30 signaling and activation of EGFR/PI3K/ERK/FAK pathway in endometrial cancer cells (Fig. 6). This evidence concerns the gene PTK2 and endometrial cancer.